Quinaprilat-eluting stents do not attenuate intimal thickening following stenting in porcine coronary arteries

Atherosclerosis

Volumn 205, Issue 1, 2009, Pages 120-125

  van Beusekom, Heleen M M ^a   Ferrero, Valeria ^b   Ribichini, Flavio ^b   van der Giessen, Willem J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

ACE inhibitor; Drug eluting stent; Experimental angioplasty; Restenosis

Indexed keywords

PHOSPHORYLCHOLINE; QUINAPRILAT; SOLVENT;

ANGIOCARDIOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY DIAMETER; ARTERY INTIMA PROLIFERATION; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DRUG EFFICACY; DRUG ELUTING STENT; DRUG MEGADOSE; HISTOPATHOLOGY; LOADING DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TREATMENT FAILURE; TREATMENT OUTCOME;

ANGIOGRAPHY; ANGIOPLASTY, BALLOON; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOOD VESSEL PROSTHESIS IMPLANTATION; CORONARY VESSELS; DRUG-ELUTING STENTS; FEMALE; HYPERPLASIA; MALE; PEPTIDYL-DIPEPTIDASE A; PHOSPHORYLCHOLINE; SWINE; TETRAHYDROISOQUINOLINES; TUNICA INTIMA;

EID: 67349178164     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.11.029     Document Type: Article

References (30)

1. Daemen M.J., Lombardi D.M., Bosman F.T., et al. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res 68 (1991) 450-456
2. Amant C., Bauters C., Bodart J.C., et al. D allele of the angiotensin I-converting enzyme is a major risk factor for restenosis after coronary stenting. Circulation 96 (1997) 56-60
3. Ribichini F., Steffenino G., Dellavalle A., et al. Plasma activity and insertion/deletion polymorphism of angiotensin I-converting enzyme: a major risk factor and a marker of risk for coronary stent restenosis. Circulation 97 (1998) 147-154
4. Ribichini F., Ferrero V., Matullo G., et al. Association study of the I/D polymorphism and plasma ACE as risk factors for stent restenosis. Clin Sci 107 (2004) 381-389
5. Powell J.S., Clozel J.P., Muller R.K., et al. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 245 (1989) 186-188
6. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Circulation 86 (1992) 100-110
7. Faxon D.P., and The Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. J Am Coll Cardiol 25 (1995) 362-369
8. Meurice T., Bauters C., Hermant X., et al. Effect of ACE inhibitors on angiographic restenosis after coronary stenting (PARIS): a randomised, double-blind, placebo-controlled trial. Lancet 357 (2001) 1321-1324
9. Jorgensen E., Kelbaek H., Helqvist S., et al. Predictors of coronary in-stent restenosis: importance of angiotensin-converting enzyme gene polymorphism and treatment with angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 38 (2001) 1434-1439
10. Toyofyuku M., Imazu M., Sumii K., et al. Influence of angiotensinogen M253T gene polymorphism and an angiotensin converting enzyme inhibitor on restenosis after percutaneous coronary intervention. Atherosclerosis 160 (2002) 339-344
11. Ribichini F., Wijns W., Ferrero V., et al. Effect of angiotensin-converting enzyme inhibition on restenosis after coronary stenting. Am J Cardiol 91 (2003) 154-158
12. Koch W., Mehilli J., von Beckerath N., et al. Angiotensin I-converting enzyme (ACE) inhibitors and restenosis after coronary artery stenting in patients with the DD genotype of the ACE gene. J Am Coll Cardiol 41 (2003) 1957-1961
13. Ribichini F., Ferrero V., Rognoni A., Vacca G., and Vassanelli C. Angiotensin antagonism in coronary artery disease: results after coronary revascularization. Drugs 65 (2005) 1073-1096
14. Clozel J.P., Muller R.K., Roux S., et al. Influence of the status of the renin-angiotensin system on the effect of cilazapril on neointima formation after vascular injury in rats. Circulation 88 (1993) 1222-1227
15. Van Belle E., Bauters C., Wernert N., et al. Angiotensin converting enzyme inhibition prevents proto-oncogene expression in the vascular wall after injury. J Hypertens 13 (1995) 105-112
16. Plosker G.L., and Sorkin E.M. Quinapril. A reappraisal of its pharmacology and therapeutic efficacy in cardiovascular disorders. Drugs 48 (1994) 227-252
17. Whelan D.M., van der Giessen W.J., Krabbendam S.C., et al. Biocompatibility of phosphorylcholine coated stents in normal porcine coronary arteries. Heart 83 (2000) 338-345
18. Lowe H.C., Schwartz R.S., Mac Neill B.D., et al. The porcine coronary model of in-stent restenosis: current status in the era of drug-eluting stents. Catheter Cardiovasc Interv 60 (2003) 515-523
19. Virmani R., Kolodgie F.D., Farb A., and Lafont A. Drug eluting stent: are human and animal studies comparable?. Heart 89 (2003) 133-138
20. van Beusekom H.M.M., Whelan D.M., van der Plas M., et al. A practical and rapid method of histological processing for examination of coronary arteries containing metallic stents. Cardiovasc Pathol 5 (1996) 69-76
21. Popma J.J., and Bashore T.D. Quantitative angiography. In: Topol E.J. (Ed). Textbook of Interventional cardiology (1994), WB Saunders, Philadelphia, PA 1052-1068
22. Schwartz R.S., Huber K.C., Murphy J.G., et al. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol 19 (1992) 267-274
23. Ohishi M., Ueda M., Rakugi H., et al. Upregulation of angiotensin-converting enzyme during the healing process after injury at the site of percutaneous transluminal coronary angioplasty in humans. Circulation 96 (1997) 3328-3337
24. Ribichini F., Pugno F., Ferrero V., et al. Cellular immunostaining of angiotensin-converting enzyme in human coronary atherosclerotic plaques. J Am Coll Cardiol 47 (2006) 1143-1149
25. Fingerle J., Muller R.M., Kuhn H., et al. Mechanism of inhibition of neointimal formation by the angiotensin-converting enzyme inhibitor cilazapril. A study in balloon catheter-injured rat carotid arteries. Arterioscler Thromb Vasc Biol 15 (1995) 1945-1950
26. Hu M., Zheng L., Chen J., et al. Mechanisms of transport of quinapril in Caco-2 cell monolayers: comparison with cephalexin. Pharm Res 12 (1995) 1120-1125
27. Schmeisser A., Soehnlein O., Illmer T., et al. ACE inhibition lowers angiotensin II-induced chemokine expression by reduction of NF-kappaB activity and AT1 receptor expression. Biochem Biophys Res Commun 325 (2004) 532-540
28. 2 receptors in neointimal formation. Circulation 106 (2002) 847-853
29. 1 receptor, and nitric oxide synthase expression in patients with coronary heart disease. Hypertension 39 (2002) 634-638
30. Ribichini F., Ferrero V., Wijns W., Matullo G., Piazza A., and Uslenghi E. Can ACE Inhibitors promote detrimental vascular effects after percutaneous injury?. Hypertension 40 (2002) e5-6